HOTH - Hoth Therapeutics' Investigational Cancer Drug Shows Encouraging Preclinical Activity In Stomach Cancers | Benzinga
Hoth Therapeutics Inc (NASDAQ: HOTH) announced that HT-KIT, a new molecular entity for advance systemic mastocytosis, achieved encouraging preclinical results.
The preclinical research was conducted over the past two years.
The initial studies aimed to assess how long HT-KIT was functional in cancerous and non-cancerous mast cells and to determine whether the cells could develop resistance to HT-KIT.
Key findings from initial studies in the mouse model show:
- HT-KIT effectively kills human mast cells that rely ...